Media

Kaleido Biosciences, a U.S.-based clinical-stage healthcare company, and BIOASTER, the French Technology Research Institute in applied microbiology, announced today the initiation of a collaborative project aiming to evaluate the immunomodulatory and homeostatic potential of the Microbiome Metabolic Therapies (MMT™) - de novo synthetized proprietary glycans developed by Kaleido to improve human health via the gut microbiome.

Extract from Allô Docteurs France 5, Recherche : identifier les bactéries du microbiote, November 2019

Targeted culturomics : innovative applications in human and animal
Mine the microbiome as a source of innovative biocompounds

INRAE and Roquette are partnering in a two-year project aimed at identifying the bacteria of the human intestinal microbiome able of degrading different types of prebiotic fibers and characterizing the biomolecules involved in this degradation.

Study of the mechanisms of action of Bacillus clausii bacteria, the main constituent of Enterogermina®, a probiotic marketed for more than 60 years for the prevention and treatment of diarrhea

INRAE is starting a research and development project in collaboration with the Microbiome Venture of DuPont Nutrition & Health, which will be led by the "Functionality of the Intestinal Ecosystem" team of Institut Micalis and the human metagenomics experts of the pre-industrial demonstrator Metagenopolis. The objective of this collaboration is to elucidate the molecular mechanisms of action of DuPont probiotic bacterial strains using a functional (meta)genomics approach.